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Abstract
Background: Early hepatocellular carcinoma (HCC) detection is difficult because low accuracy of surveillance tests. Genome-
wide analyses were performed using HCV-cirrhosis with HCC to identify predictive signatures.
Methodology/Principal Findings: Cirrhotic liver tissue was collected from 107 HCV-infected patients with diagnosis of HCC
at pre-transplantation and confirmed in explanted livers. Study groups included: 1) microarray hybridization set (n = 80)
including patients without (woHCC= 45) and with (wHCC= 24) HCC, and with incidental HCC (iHCC= 11); 2) independent
validation set (n = 27; woHCC= 16, wHCC= 11). Pairwise comparisons were performed using moderated t-test. FDR,1% was
considered significant. L1-penalized logistic regression model was fit for woHCC and wHCC microarrays, and tested against
iHCC. Prediction model genes were validated in independent set by qPCR. The genomic profile was associated with genetic
disorders and cancer focused on gene expression, cell cycle and cell death. Molecular profile analysis revealed cell cycle
progression and arrest at G2/M, but progressing to mitosis; unregulated DNA damage check-points, and apoptosis. The
prediction model included 17 molecules demonstrated 98.6% of accuracy and correctly classified 6 out of 11 undiagnosed
iHCC cases. The best model performed even better in the additional independent set.
Conclusions/Significances: The molecular analysis of HCV-cirrhotic tissue conducted to a prediction model with good
performance and high potential for HCC surveillance.
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Introduction
Chronic infection with hepatitis C virus (HCV) is considered
a major risk for chronic liver failure. Recent epidemiological
studies and data from the World Health Organization (WHO;
www.who.int) estimated the global prevalence around 160–170
million of people chronically infected with HCV [1]. In the United
States (USA), HCV infection is considered the main blood-borne
disease with an estimated prevalence range of 1.3–1.9% with
32,973 new reported cases only in 2009 [1–3]. But this tendency
might have a negative slope for the following years. Recent
estimations predicted a decreasing HCV-infection prevalence for
several regions, including the USA, of about 22–24% for the 20
year decade [4,5]. However, chronic liver infection with HCV
associates with the development of hepatic malignancies. Hepa-
tocellular carcinoma (HCC) is considered the main primary liver
cancer and the third leading cause of death worldwide [6].
Chronic HCV infection is the second most common cause of all
HCCs, and the leading etiology in Japan, Egypt, and within the
USA [7–9]. However, the carcinogenic processes leading to HCC
development in HCV-cirrhosis cases are not yet well understood.
It has been postulated that direct and indirect interactions between
HCV-encoded proteins and host hepatic cells may contribute to
the malignant process [10]. In addition to this, the chronic
inflammation scenario accompanied by immune-mediated de-
struction of infected hepatocytes, oxidative stress, virus-induced
apoptosis, DNA damage leading to genomic heritable aberrations,
and continuous hepatic regeneration processes may also be
involved in promoting HCC development within the HCV-
cirrhotic background [9,10].
Liver transplantation (LT) demonstrated to have therapeutic
advantages as surgical treatment option of patients with early
HCC [11]. Moreover, end stage liver disease due to chronic HCV
infection-based cirrhosis is the principal contributor to the LT
procedure rates in European countries, Japan, and the USA
[11,12]. Furthermore, the priority allocation system of the United
Network for Organ Sharing (UNOS) organization ascribes extra-
points to those HCC affected patients who meet currently adopted
inclusion criteria [13–15]. As a consequence of the poor clinical
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outcomes of patients with hepatitis C-induced cirrhosis and who
are diagnosed with advanced hepatocellular carcinoma stages
improved markers for early detection are needed. Nowadays,
surveillance for HCC is recommended every 6 to 12 months in
patients at high risk, but a strict consensus has not been reached
yet [16,17]. Conventional HCC surveillance tests are based on
radiological imaging techniques (US, CT scan, and MRI) and/or
serological biomarkers (e.g. alpha-fetoprotein). In spite of recent
technological advances, imaging-based methods still unfortunately
lack of sufficient accuracy and sensitivity for early diagnosis of
small HCC lesions (,2 cm) mainly associated with the nodular
cirrhotic liver background [16,18,19]. In a similar manner, alpha-
fetoprotein demonstrated to be controversial as consequence of its
low diagnostic performance as HCC screening biomarker, while
other promising circulating molecules need further clinical
evaluation [16,20].
A better understanding of the cirrhotic liver tissue biology in
chronically HCV-infected patients might reveal involved carcino-
genic promoter mechanisms in HCC development, and thus
improving the screening biomarker discovery. Genomic-based
approaches using oligonucleotide microarrays represent reliable
technology of choice. In this study, a transcriptome -based analysis
was performed in HCV-cirrhotic non-tumor tissue from patients
with and without HCC aiming to, 1) biologically characterize the
molecular events leading to HCC development in the HCV-
cirrhotic tissue, 2) identify a multigenic classifier capable of
detecting the presence of hepatocellular carcinoma in cirrhotic
tissues, and 3) validate the genes included into the identified
multigenic classifier in an independent set of patients.
Materials and Methods
Patients and Tissue Samples Collection
This study has been approved by the Institutional Review Board
at Virginia Commonwealth University, and written informed
consent was obtained from all patients. The present study included
107 HCV-cirrhotic patients who underwent LT treatment for end-
stage liver disease. All patients were screened for HCC lesions
previous to LT surgery by radiological techniques (CT scan and
MRI). Histopathological examination was performed by serially
sectioning up to 5 mm for each explanted liver. Demographic and
clinico-pathological characteristics were collected for all included
patients (Table 1). Cirrhotic tissue (non-tumor) was obtained from
each HCV-cirrhotic liver and snap-frozen in liquid nitrogen or
collected in RNAlaterTM reagent (Ambion Inc., Austin, TX, USA)
following manufacturer instructions, and stored at 280uC until
use.
RNA Isolation and Microarray Hybridization
Total RNA was extracted from HCV-cirrhotic liver tissues
using TRIzol reagent (Life technologies, Carlsbad, CA, USA)
following the Affymetrix GeneChipH Expression Analysis Manual
(Affymetrix, Santa Clara, CA, USA) guidelines and recommenda-
tions. All isolated RNA samples followed and met purity and
integrity quality control criteria previously established in our
laboratory [21]. Microarray hybridization was performed for 80
HCV-cirrhotic patients including cases without HCC (woHCC,
n=45), with HCC (wHCC, n= 24), and with incidental HCC
(iHCC, n= 11) (Figure 1 and Table 1). Reactions for cDNA
synthesis and in vitro transcription for labeled cRNA probe,
AffymetrixTM HG-U133A v2.0 GeneChipH microarray hybrid-
ization, image generation, and probesets reading process were
performed as reported previously [22].
Microarray Quality Control and Data Analysis
Eighty Affymetrix HG-U133Av2 GeneChips were available
from 80 HCV-cirrhotic patients undergoing LT, including 45
woHCC subjects, 11 iHCC subjects, and 24 wHCC subjects.
Quality of the hybridized arrays was assessed by examining the
average background, scaling factor, percent of probe sets called
present by the detection call algorithm, and the 39:59 ratio for
GAPDH and ACTIN. Additionally, probe level linear models using
affyPLM were fit and plots of the residuals were examined for each
hybridized GeneChip. Thereafter, control probe sets and probe
sets considered absent in all samples were removed [23], leaving
18,017 probe sets for statistical analysis. For each probe set,
a moderated t-test was used to compare cirrhosis woHCC versus
cirrhosis wHCC or iHCC; cirrhosis woHCC versus cirrhosis
wHCC; as well as to compare cirrhosis woHCC versus cirrhosis
with iHCC using the limma Bioconductor package [24,25] in the
R programming environment [26]. To adjust for the multiple
hypothesis tests, the p-values were used in estimating the false
discovery rate (FDR) using the Benjamini and Hochberg method
[27]. Probe sets having an FDR,0.01 were considered significant.
Predictive Class Classifier Analysis
To predict group membership using the gene expression data,
an L1-penalized logistic regression model was fit using the glmpath
package in the R programming environment [28] using the
subjects with cirrhosis woHCC and those wHCC as the training
set. The Akaike Information Criterion (AIC) was used to select the
best fitting model. To evaluate model performance, the subjects
with iHCC were used as an independent test set (Figure 1).
Supervised hierarchical clustering analysis using Ward’s method
was applied to the identified gene expression matrix including all
samples from woHCC, wHCC, and iHCC groups. A heatmap was
also represented in accordance and together with the obtained
sample clusters.
Gene Ontology and Gene Pathway Analysis
Ingenuity Pathway Analysis (IPA) tool version 9.0 (http://www.
ingenuity.com) was applied for gene networks interaction and
pathway function analysis. Statistically differentially expressed
genes identified from the wHCC vs. woHCC, iHCC vs. woHCC,
and aHCC (wHCC + iHCC) vs. woHCC pairwise comparisons
were incorporated in a list containing probesets ID, Gene symbol,
Entrez gene ID as clone identifier, probeset intensity values for
each study population, p-value, q-value, and fold change values.
Identified genes were mapped in the Ingenuity Knowledge Base
(genes + endogenous chemicals) as the reference set in IPA.
Real Time PCR Assays
The expression of genes included into the best fitting prediction
model were validated in an independent HCV-cirrhotic tissue
sample group (independent validation set, n = 27; Figure 1) by real
time PCR (qPCR) using TaqmanH assays (Applied-Biosystems,
Inc.). Clinicopathological characteristics of the independent valida-
tion set are described inTable 1. The gene list andTaqmanH assays
used for validation included: RBPMS (Hs00199302_m1), ACSL6
(Hs00362960_m1), DPP4 (Hs00175210_m1), CENPN
(Hs00218401_m1), C2orf43 (Hs00222492_m1), KNTC1
(Hs00206854_m1), MLL (Hs00610538_m1), SCMH1
(Hs00984275_m1), and TNS1 (Hs00917032_m1). The qPCR
amplification signal for each gene was normalized to the expression
of GAPDH encoding gene (pre-developed TaqmanH assay) as
internal standard. Gene expression analysis was performed using
delta-Ct valuemodel (averageCt gene – averageCt GAPDH). Statistical
Molecular Markers and HCV-HCC Surveillance
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significances between wHCC vs. woHCC groups were evaluated by
analysis of variance (ANOVA) test. A p-value,0.05 was considered
statistically significant.
Results
Demographic and Clinicopathological Characteristics of
Patients Included in the Study
A total of 107 HCV-cirrhotic liver tissue samples from
individual patients were included in the study. The study design
is described in Figure 1.
As it was previously mentioned, the demographic and
clinicopathological characteristics of all HCV-cirrhotic patients
included in the study and separated by groups are summarized in
Table 1. All patients in this study cohort were infected with HCV
genotype 1. From the group of patients used for microarray
hybridization, 24/80 (30.0%) of cases were HCC lesions detected
by radiology pre-LT. No HCC lesions were detected in 56 patients
(70.0%) at pre-LT stage, but the pathological examination
identified incidental HCC lesions in 11 (19.6%) of these cases.
The remaining 45 HCV-cirrhosis cases were confirmed as without
HCC. Demographically, the HCC patient population was
significantly older than those patients without HCC. No statistical
Table 1. Demographic and clinicopathological characteristics of HCV-cirrhotic patient groups.
Study sets Microarray hybridization set Independent validation set
HCV-cirrhosis groups
WoHCC
(n=45)
Whcc
(n=24)
iHCC
(n=11) p-value woHCC (n=16)
wHCC*
(n =11) p-value
Age (years) Mean 6 SD (range) 50.666.2
(30–62)
54.667.2
(43–68)
54.767.9
(39–65)
0.0349 52.966.0 (40–62) 51.865.6 (44–64) 0.6296
Gender Male 37 19 11 0.3148 15 11 0.3003
Female 8 3 0 1 0
Race White 38 18 8 0.6637 11 8 0.8941
Black/African
American
6 2 1 4 2
Other 1 2 2 1 1
Waiting list time in days Mean 6 SD (range) 2726345
(2–1580)
3556627
(15–2100)
3286474
(4–1525)
0.7726 2536389 (61–1408) 2186335 (13–1107) 0.8271
MELD score at LT Mean 6 SD (range) 20.067.8
(6–39)
23.464.4
(12–29)
21.667.3
(13–37)
0.1749 20.266.2 (12–36) 23.262.1 (22–28) 0.1977
Tumor stage (%) T1 1 (4.2) 3 (27.3) 0.2297 2 (18.2) NA
T2 16 (66.7) 6 (54.5) 9 (81.8)
T3 5 (20.8) 1 (9.1) 0 (0.0)
T4 2 (8.3) 1 (9.1) 0 (0.0)
HCC Lesions (%) Single 9 (37.5) 5 (45.4) 0.6556 7 (63.4) NA
Multiple 15 (62.5) 6 (54.6) 4 (36.4)
Size (cm) Mean 6 SD (n; range) 2.361.3
(44; 0.4–5.2)
1.360.8
(20; 0.1–4.0)
0.0040 2.261.4
(16; 0.7–6.0)
NA
(*)Histopathological examination identified one incidental HCC viable unique lesion (size: 1.7 cm) in the explanted liver from one HCV-cirrhosis case of the independent
patients’ set. P-values were calculated among HCV-cirrhotic groups for each study set.
doi:10.1371/journal.pone.0040275.t001
Figure 1. Schematic representation of the study design. HCV-cirrhotic tissue samples were divided in two main groups: 1) microarray
hybridization (n = 80), and 2) independent validation set (n = 27), represented in gray squares. Pairwise comparisons among woHCC, wHCC, and iHCC
groups of hybridized microarrays were performed for molecular pathway analyses. L1-penalized regression model was fit for woHCC and wHCC
groups with hybridized microarrays (training set). The iHCC group was the test set for the identified prediction model. The independent set (n = 27)
validated the expression of 9 randomly selected genes from the prediction model.
doi:10.1371/journal.pone.0040275.g001
Molecular Markers and HCV-HCC Surveillance
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e40275
differences were found regarding gender and race, time on waiting
list, MELD score at LT, and HCC TNM stage at LT. Moreover,
most of incidental HCC lesions were small (ranged between 0.1–
2.2 cm in size); with only one T4 HCC diffuse lesion was identified
in a patient with macroregenerative cirrhosis. Ablation treatment
was performed in all HCC patients at pre-LT (combined RFA,
TACE).
The independent validation set of patients included 26 cases
diagnosed without (n = 16) and with (n = 10) HCC at pre-LT using
the conventional diagnosis methods. An incidental HCC lesion
(1.7 cm in size) was identified in one patient in the analysis of the
explanted liver. However, for analysis purposes, the patient was
classified within HCV-cirrhosis with HCC. No significant
differences were identified for age, gender, race, waiting time for
LT, and MELD score at LT. All patients with HCC were staged
as T1/T2 (Table 1).
Differential Gene Expression Analysis and Molecular
Pathways Identification
After oligonucleotide microarrays hybridization, control and
absent calls were removed and a total of 18,017 probesets (Pset)
were available for statistical analysis. Pairwise comparison analyses
were performed between: 1) wHCC (n=24) vs. woHCC (n= 45),
2) iHCC (n= 11) vs. woHCC (n= 45), and 3) aHCC (n= 35) vs.
woHCC (n= 45) to identify differentially expressed Psets. From
the analysis, the total of significantly and differentially expressed
Psets was 1,252 (1,053 genes), 443 (392 genes), and 2,357 (1,945
genes), respectively. The analysis of biological functions was
conducted by IPA tool in each of the three performed pairwise
comparisons. In all three comparisons the pathway analysis
revealed a similar deregulated genomic component, which was
strongly associated with genetic disorders, and cancer as principal
pathology. Moreover, the most significant molecular functions
included gene expression, cell cycle and cell death regulation. In
consideration to the similarities of molecular pathways among
analyses, the complete molecular biological analysis was per-
formed in the aHCC vs. woHCC pairwise comparison due to
higher HCV-cirrhosis cases and number of identified genes.
From the analysis, cancer-related processes (tumorigenesis,
carcinoma, neoplasia, and transformation), cell cycle (progression,
division, interphase, and stage), cell death (apoptosis), cellular
growth and proliferation, and gene expression regulation were the
mostly significant (p,1.0E-10) associated molecular and cellular
functions (Figure 2). Gene ontology and molecular pathways
identified associated network functions related to cellular assembly
and organization; DNA replication, recombination, and repair;
genetic disorders, hematological disease, and cancer; and cell cycle
control and cell morphology. Top five canonical pathways from
a total of 120 identified as significantly (p#0.01) altered between
cirrhosis aHCC vs. woHCC included PI3K/AKT signaling
(p =3.46E-09), molecular mechanisms of cancer (p =1.16E-08),
PTEN signaling (p=1.04E-07), apoptosis signaling (p=1.64E-07),
and chronic myeloid leukemia signaling (p=1.95E-06). The
canonical pathways complete list is detailed in Table S1.
From the analysis of hepatic disease associated function
networks to provide key processes involved in organ detriment,
the most significantly identified hepatotoxic alterations included
liver necrosis/cell death (p=3.80E-04 - 6.38E-01), HCC
(p=1.95E-03 - 4.89E-02), cirrhosis (p=5.59E-03 - 6.66E-02),
proliferation (p=1.39E-02 - 5.99E-01), and regeneration of the
liver (p=1.69E-02 - 2.62E-01). Genes involved in cirrhosis
development (ABCG2, CTNNB1, B2M, IFNAR1, IFNAR2), and
hepatic cholestasis (CYP7B1) were found significantly down-
regulated in patients without HCC.
Molecular Mechanisms Associated with HCC
Development
To better understand HCC associated molecular events,
a detailed gene by gene analysis was performed including those
differentially expressed molecules related to cell cycle and
apoptosis control. Overall, critical genes encoding for positive cell
cycle progression factors (CCND1, CDK1, CDK2, E2F3, EIF4E, and
MDM2) were found significantly up-regulated in HCV-cirrhosis
with HCC. Conversely, HCV-cirrhotic samples with absence of
HCC till conserved high expression levels of genes exerting
negative cell cycle regulation (JUNB, CDKN2C, LIF, FOXO4,
HMGA1, KLF4, NFKBIA, MYB, FZR1, and CDK11A/CDK11B)
throughout all cell cycle phases.
Then, the genomic profile was analyzed for each cell cycle
phase in concordance with each gene function (Figure 3). The
complete list including all cell cycle-related genes classified by
phase with expression, significant, biological role, and cell cycle
impact is detailed in Table S2. From the analysis, most of genes
associated with positive G1 phase and G1/S transition progression
were up-regulated while arrest G1 phase-related genes were down-
regulated in HCV-cirrhotic tissue with HCC. The expression of
G1/S transition involved genes was equally up-and down-
regulated. However, the majority of S phase intro-related genes
were up-regulated as counterpart of S phase blockade down-
regulated molecules in association with HCC development. These
observations suggest cell cycle progression throughout initial (G1)
and DNA synthesis (S) phases, but with a potential functional G1/
S cell cycle checkpoint.
However, genes involved in negative cell cycle regulation at G2
and G2/M were found up-regulated together with G2/M
checkpoint DNA damage-inducible genes (Figure 3). DNA
double-strand break repair by homologous recombination associ-
ated genes (NBS1, RAD50, RAD 52, and RAD54) were also found to
be significantly up-regulated (Figure S1). Spindle formation and
chromosomal integrity associated genes were significantly up-
regulated in favor of mitosis progression and cell proliferation in
HCV-cirrhosis associated with HCC independently of the G2/M
check-point cell cycle arrest trend.
Apoptosis canonical pathway analysis revealed a pro-apoptotic
trend associated with DNA damage and homeostasis, and may be
triggered by caspase-independent DNA fragmentation (Figure 4).
Pro-apoptotic (BAX, BAD, CDC2, and AIF) and anti-apoptotic
(BCL-2, BCL-XL, and MCL1) genes mostly related to DNA
damage were found to be up and down-regulated, respectively.
Interestingly, genes associated with early cell cycle control (G1/S)
and apoptosis in liver cells (TGFb1, EGFR) were found down-
regulated in HCV-cirrhosis with HCC. The TGFb1-encoding
gene was identified as central down-regulated molecule of the top
scored (score: 43) associated network function (Figure S2). In
addition, NOTCH1 and GADD45B encoding genes were found
downregulated when cirrhotic patients develop HCC in concor-
dance with previous reports [29,30].
HCV-cirrhosis associated with HCC denotes increased cell
proliferation over a pro-apoptotic and functional cell cycle
checkpoints, but maybe associated not resolved DNA damage
and accumulation of chromosomal aberrations leading to HCC
development.
Class Prediction Model for HCV-cirrhosis with HCC as
Classification Variable
The study of differentially expressed genes in HCV-cirrhotic
tissues may set the basis for the establishment of HCC predictive
genomic signatures. To determine the best multigenetic prediction
Molecular Markers and HCV-HCC Surveillance
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e40275
classifier for HCV-cirrhosis with associated HCC an L1-penalized
logistic regression model was fit including wHCC and woHCC
groups (n = 69) as training set (Figure 1). The best fitting
regression prediction model included 17 significantly and differ-
entially expressed Psets representing unique genes (Table 2).
Briefly, those genes were found to be associated with cell death,
growth and proliferation, tumor morphology, cellular develop-
ment, cell movement, gene expression, and DNA replication,
recombination, and repair. The calculated diagnostic performance
of the prediction model displayed an accuracy of 98.6%, with an
estimated sensitivity, specificity, positive and negative predictive
values of 100%, 95.8%, 97.8%, and 100%, respectively, as
illustrated by the receiver operating characteristic curve (Figure
S3). Following, the prediction model was evaluated against iHCC
cases (Figure 1). Among the undiagnosed iHCC cases, 54.5% (6/
11) were correctly classified as HCV-cirrhotic patients with HCC.
These results are of high clinical relevance because iHCC cases are
critical since the HCC diagnosis failed by conventional tests at pre-
LT stage.
The dimensionality of the gene expression dataset for those
genes identified by the prediction model was reduced using
classical multidimensional scaling. The resulting three-dimensional
plot showed unique group of wHCC cases including 9 of 11
(81.8%) iHCC cases. Similarly, 39 of 45 (86.7%) of woHCC were
separated from the other cases, and 2 of 11 (18.2%) iHCC cases
were grouped together with woHCC cases (Figure 5A). A 2-D
side-scatter graphic is further illustrated for additional details in
Figure S4. Following, a supervised hierarchical clustering was
performed including all Psets from the predictive model
(Figure 5B). The resulting dendrogram associated the 80 HCV-
cirrhotic cases in two well-defined groups in accordance with
HCC status.
Figure 2. Molecular and cellular functions deregulated in HCV-cirrhosis with HCC. A p-value expressed as –log range of 10.2 to 30.0 was
applied to identify the most significant cellular functions. Present functions and sub-groups are indicated in purple. Color intensity indicates the
statistical significance for differential expressed function as the dark color the most significant. Involved cellular functions were identified using IPA
tool.
doi:10.1371/journal.pone.0040275.g002
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Validation of the Prediction Model Genes using QPCR in
and Independent Set of Patients
The identified genes from the prediction model were validated
in an additional independent sample set of patients using QPCR
(Figure 1). From the analysis, twelve randomly selected genes
from the best LASSO-model were evaluated and nine were also
found to be significantly differentially expressed in the indepen-
dent sample set (Table 3). These results indicate a correlating
expression trend with respect to microarray assays. Four validated
genes (RBPMS, ACSL6, DDP4, and CENPN) were also previously
identified in a similarly designed pilot study to test the L1-
penalized logistic regression model algorithm [31].
Figure 3. Cell cycle associated genes scheme. The sketch represents the cell cycle phases and interphases. Phases are named inside the main
circle. Black bars indicate interphases. The G2/M interphase is indicated by a red bar. Cell cycle progression is illustrated by a round green arrow and
potential progression by dashed blue arrow. Cell cycle blockade and progression are indicated by a red T and a black arrow head, respectively,
whereas the size and thickness is proportional to the cell cycle regulation. Genes involved in each phase are listed in tables depending on the cell
cycle phase. Red: up-regulation, green: down-regulation; genes involved in positive cell cycle progression are underlined.
doi:10.1371/journal.pone.0040275.g003
Molecular Markers and HCV-HCC Surveillance
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Core analysis was performed to interpret the data set in the
context of biological processes, pathways and molecular networks.
Molecular pathway analyses (http://www.ingenuity.com) directly
associated the nine validated genes with cancer development and
cell death. The most significant molecular functions included cell
cycle mainly associated with arrest at G2/M transition (DDP4),
progression (KNTC1, MLL, SCMH1), and mitosis (CENPN); and
cell-to-cell signaling and interaction (TNS1), RNA processing
(RBPMS), and cell proliferation (ACSL6).
To visualize how the nine set of validated genes differentiate
between HCV-cirrhosis regarding HCC diagnosis, a quadratic
discriminate analysis was performed including all samples from
the independent set (Figure 6). The resulting canonical plot
showed two well-defined sets of HCV-cirrhotic samples sepa-
rated in accordance with HCC diagnosis without miss-classifi-
cation.
Figure 4. Apoptosis canonical pathway. The differentially expressed molecules are represented by color as up-regulated (red) and down-
regulated (green). Color intensity indicates fold change values estimation for each molecule.
doi:10.1371/journal.pone.0040275.g004
Molecular Markers and HCV-HCC Surveillance
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Discussion
Hepatocellular carcinoma is frequently associated with ad-
vanced cirrhosis due to chronic hepatitis C. Progressive liver
damage until HCC development in chronic HCV-infected
patients encompasses deregulation of molecular pathways trigger-
ing malignant transformation. In this sense, the HCV-cirrhotic
background has been further considered as a premalignant state
[32]. Despite of animal and in vitro model establishment difficulties
to study HCV infection outcomes, virus protein - host direct and
indirect interactions were found thoroughly associated with liver
cancer development. In HCV-cirrhotic patients, HCC is the final
result of several rounds of hepatocytes destruction and regener-
ation by virus-induced immune-mediated mechanism and tissue
damage associated processes such as oxidative stress, which impact
on chromosomal DNA stability [9,10,33].
The insight into deregulated molecular mechanisms in HCV-
cirrhotic tissue background embodies the understanding of malig-
nant transformation. The present study analyzed the molecular
profile associated with HCC development in human liver cirrhotic
tissue from patients chronically infected with HCV, and who
underwent LT. The microarray-based profiling analysis was found
to be clearly associated with a carcinogenic component signed by an
altered cell cycle regulation, cell death by apoptosis, cellular growth
and proliferation. Similarly pre-cancerous genomic profiles were
detected in previous studies focused on gene expression analysis of
dysplastic nodules from advanced HCV-cirrhosis, and even in
patients infected with HCV genotype 3 [34–36].
The study initially aimed to analyze the molecular mechanisms
involved in hepatic malignancy development. Regulation of cell
cycle progression appears as the principal altered cellular function
in HCV-cirrhosis. The recent report from Kannan et al., [37]
evaluated the HCV impact on cell cycle regulation and postulated
a positive cell cycle progression until arrest at G2/M interphase
with blockage to mitosis entrance in a HCV-infected hepatoma
cell line model. In accordance with these results, the identified
expression profile of cell cycle-related genes suggested a similar
G2/M blockage trend in HCV-cirrhosis associated to HCC. In
addition, the present results also suggested functional cell cycle
checking mechanism at G1/S interphase in spite of unrestricted
progression until G2/M.
It is well-understood that HCV induces strong cellular oxidative
stress, which derive in DNA damage events and provoke
accumulation of genomic mutations [38,39]. Pro-mutagenic
DNA lesions due to oxidative stress were reported to be more
frequently in chronic HCV-infected patients [40]. From the study
results, DNA damage check-point associated genes at G2/M were
found significantly up-regulated indicating increased rates of DNA
abnormalities in HCV-cirrhotic patients with HCC. Impaired
DNA repair mechanisms due to demonstrated interactions with
HCV non-structural proteins and prevalence of reactive oxygen
and nitrogen species have been proposed as cause of HCC
development in chronic HCV infection [38,39,41]. For instance,
up-regulation of DNA repair genes in HCV-cirrhosis associated
with HCC may be in response to a compensatory effect to
oxidative stress and virus protein-induced inhibition on the DNA
repair pathway.
Hepatocyte apoptosis represents a hallmark of chronic HCV
infection in cirrhotic patients. It has been further reflected in the
characterized genomic profile of HCV-cirrhosis with HCC. HCV
core protein demonstrated to be by itself a pro-apoptotic factor
through its interaction with the human myeloid cell factor 1 (Mcl-
1) protein mimicking NOXA, the BH3-only member of the Bcl-2
family [42]. From the present study, key anti-apoptotic genes were
found down-regulated maybe in response to unrepaired DNA
adducts and mitochondrial membrane instability due to perma-
nent oxidative stress induced by HCV. However, the HCV core
protein itself was also implicated as tumor initiator inducing
proliferation, anti-apoptosis and oxidative stress-related DNA
adducts by activation of c-jun and stat-3 [43]. Indeed, the
molecular profile proposes mitosis progression and cell pro-
liferation, which has been demonstrated by other report to occur
under the mitotic checkpoint inhibition in HCV infected
Table 2. Best fitting prediction model for HCC detection in HCV-cirrhotic patients.
Probeset ID Gene symbol Entrez ID Gene name
200601_at ACTN4 81 Actinin, alpha 4
201291_s_at TOP2A 7153 Topoisomerase (DNA) II alpha 170kDa
201500_s_at PPP1R11 6992 Protein phosphatase 1, regulatory (inhibitor) subunit 11
201605_x_at CNN2 1265 Calponin 2
205114_s_at CCL3 414062 Chemokine (C-C motif) ligand 3
206316_s_at KNTC1 9735 Kinetochore associated 1
209488_s_at RBPMS 11030 RNA binding protein with multiple splicing
211207_s_at ACSL6 23305 Acyl-CoA synthetase long-chain family member 6
211478_s_at DPP4 1803 Dipeptidyl-peptidase 4
212080_at MLL 4297 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)
219202_at RHBDF2 79651 Rhomboid 5 homolog 2 (Drosophila)
220726_at IGHD6–19 28486 Immuno-globulin heavy diversity 6–19
221216_s_at SCMH1 22955 Sex comb on midleg homolog 1 (Drosophila)
221748_s_at TNS1 7145 Tensin 1
222118_at CENPN 55839 Centromere protein N
222192_s_at C2orf43 60526 Chromosome 2 open reading frame 43
34406_at PACS2 23241 Phosphofurin acidic cluster sorting protein 2
doi:10.1371/journal.pone.0040275.t002
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hepatocyte [44]. All of this may allow cell proliferation carrying
chromosomal aberrations and promoting a perfect pre-stage
scenario for HCC development.
Accurate diagnosis and staging of HCC lesions in HCV-
cirrhotic patients is of high importance for treatment and decision
taking for surgical procedure. Moreover, appropriate HCC lesion
Figure 5. Best fitting prediction model for HCC identification in HCV-cirrhotic patients. L1-penalized regression model identified 17
differentially expressed Psets as listed in Table 2. A) Three-dimensional plot derived from applying classical multidimensional scaling (MDS) to the
gene expression dataset for those genes identified by the L1-penalized regression model. Individual samples are represented by a colored square for
wHCC (green), woHCC (blue), and iHCC (red). B) Two-way supervised hierarchical clustering and heatmap using ward’s method including all training
set samples and Psets identified by the best fitting model.
doi:10.1371/journal.pone.0040275.g005
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diagnosis and staging allows access of HCV-patients to liver
transplantation [12]. As consequence, the identification of suitable
markers for early HCC diagnosis may reduce time to trans-
plantation and thereby yield improved patient outcomes. The
present study proposed a multigenic prediction model consisting of
17 differentially expressed genes able to accurately predict HCC
lesions from the HCV-cirrhotic background with acceptable
estimated analytical performance. Current HCC diagnosis and
surveillance techniques are based on imaging radiological tech-
niques and serological assays. However, the accurate HCC
detection is often in an inverted relationship with the lack in
efficiency of radiological imaging-based techniques, which directly
correlates with the identification of incidental HCC lesions in
explanted livers post-LT. Small tumor lesion size alone or
combined with macronodular cirrhosis represent the most
common obstacles for conventional imaging techniques
[16,18,19]. In addition, infrequent HCC lesion variants such as
diffuse cirrhosis-like HCC consisting of very small and numerous
tumor nodules homogeneously distributed also attempt against to
the proper radiological detection since it mimics a cirrhotic
background [45]. Hereby, the proposed multigenic classifier was
able to diagnosis iHCC lesions in more than 50% of the
undiagnosed cases from a group of HCV-cirrhotic patients with
iHCC. As consequence, the promising diagnostic power of the
predictive gene signature might become of high importance for
routine liver biopsies to rule out HCC in HCV-cirrhotic patients
and contribute to the diagnostic arsenal.
Despite invasiveness of liver biopsy and the diagnostic
limitation, the identified genomic signatures may appear as
valuable biomarkers and may provide an extra tool in HCC
diagnosis for the clinician.
Table 3. Independent validation study of the genes included in the prediction model.
Gene ID Entrez ID Gene name
Fold change
(wHCC vs.
woHCC) p-value
ACSL6 23305 Acyl-CoA synthetase long-chain family member 6 2.1 0.004
CENPN 55839 Centromere protein N 1.7 0.005
RBPMS 11030 RNA binding protein with multiple splicing 21.6 0.032
DPP4 1803 Dipeptidyl-peptidase 4 2.1 0.004
C2orf43 60526 Chromosome 2 open reading frame 43 1.7 0.010
KNTC1 9735 Kinetochore associated 1 1.6 0.047
MLL 4297 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) 21.7 0.023
SCMH1 22955 Sex comb on midleg homolog 1 (Drosophila) 1.6 0.046
TNS1 7145 Tensin 1 21.7 0.050
doi:10.1371/journal.pone.0040275.t003
Figure 6. Identification of HCV-cirrhosis with and without HCC by qPCR validated genes. Canonical plot derived from applying quadratic
discriminate analysis to nine validated genes from the best L1-penalized regression model in an independent set of HCV-cirrhotic samples. The 95%
confidence ellipses of HCV-cirrhosis with (wHCC) and without HCC (woHCC) are illustrated in red and blue ovals, respectively. Individual samples are
indicated by red (wHCC) and blue (woHCC) squares.
doi:10.1371/journal.pone.0040275.g006
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In summary, the present study provided the genomic profile
associated with HCC development in human HCV-infected
cirrhotic livers, also corroborating in part previous in vitro studies.
More importantly, a multigenic predictive classifier with high
accuracy is proposed to identify HCC lesions only testing cirrhotic
background. Further analyses in prospective patients’ cohorts are
required to properly establish the clinical impact of the proposed
genomic signature on HCC surveillance. Even more, the
associated evaluation with currently recommended methods is
crucial to definitely increase the HCC detection diagnostic
performance and reduce to null the incidental HCC lesion rates.
Supporting Information
Figure S1 DNA double-strand break repair by homolo-
gous recombination pathway. Up-regulated molecules in
HCV-cirrhosis samples associated with HCC are colored in red.
(TIF)
Figure S2 Top associated network functions. The present
associated network function was identified as top with a score of
43. The differentially expressed molecules are represented by color
as up-regulated (red) and down-regulated (green). Color intensity
indicates fold change values estimation for each molecule. (*)
Molecules identified by at least two different Psets.
(TIF)
Figure S3 Best fitting model Receiver Operating Char-
acteristic (ROC) curve. The ROC curve was established using
samples from wHCC and woHCC groups. The iHCC samples
were not included. Percentages for sensitivity (Sens), specificity
(Spec), positive predictive value (PV+), and negative predictive
value (PV-) are indicated at the top left.
(EPS)
Figure S4 2D-side scatter plot for best fitting model. All
samples groups from training set were included. A red line divide
the graphic to better identified the samples distribution depending
on pathological characteristics.
(TIF)
Table S1 Complete list of canonical pathways differen-
tially expressed between HCV-cirrhotic liver tissues
from patients with and without hepatocellular carcino-
ma.
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Table S2 Cell cycle deregulated genes HCV-cirrhotic
tissue from patients with hepatocellular carcinoma.
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